Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Revenue projections:

Revenue projections for ELV
Revenue projections for ELV

Elevance Health, Inc.'s revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 1.479000
forwardPE 13.426105
debtToEquity 72.299000
earningsGrowth -0.168000
revenueGrowth 0.026000
grossMargins 0.258910
operatingMargins 0.053030
trailingEps 23.600000
forwardEps 29.247500

ELV's current ratio of 1.479 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects ELV's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
Elevance Health, Inc.'s Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
ELV's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
ELV's negative gross and operating margins point to financial difficulties, as the company is unable to generate profit from its core operations or production. This could signal broader problems in cost management or declining sales.
ELV's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in ELV's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for ELV
Price projections for ELV

ELV's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for ELV
Insider Transactions for ELV


There were 4 ELV sales transactions, at market price of 353.5238800048828.ELV saw 3 buying transactions, each while market price hovered at 291.27161661783856.The insider transaction data does not present a strong trend, leaving ambiguity about the company’s overall strategic or financial direction.

Recommendation changes over time:

Recommendations trend for ELV
Recommendations trend for ELV


The recent buy bias from analysts suggests ELV is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, ELV appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.